Sarepta Therapeutics, Inc.
SRPT
$105.56
-$2.11-1.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.90B | 1.64B | 1.50B | 1.40B | 1.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.90B | 1.64B | 1.50B | 1.40B | 1.24B |
| Cost of Revenue | 1.12B | 1.03B | 946.21M | 997.99M | 1.03B |
| Gross Profit | 778.36M | 609.29M | 558.78M | 405.31M | 215.61M |
| SG&A Expenses | 557.87M | 525.70M | 518.39M | 498.16M | 481.87M |
| Depreciation & Amortization | 2.41M | 2.57M | 2.40M | 1.98M | 1.56M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.68B | 1.56B | 1.47B | 1.50B | 1.51B |
| Operating Income | 218.08M | 81.03M | 37.99M | -94.83M | -267.82M |
| Income Before Tax | 260.77M | 129.40M | 62.22M | 34.06M | -520.10M |
| Income Tax Expenses | 25.54M | 7.56M | 14.93M | 17.16M | 15.88M |
| Earnings from Continuing Operations | 235.24 | 121.85 | 47.30 | 16.90 | -535.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 235.24M | 121.85M | 47.30M | 16.90M | -535.98M |
| EBIT | 218.08M | 81.03M | 37.99M | -94.83M | -267.82M |
| EBITDA | 255.81M | 119.67M | 77.75M | -53.00M | -223.43M |
| EPS Basic | 2.46 | 1.29 | 0.48 | 0.14 | -6.10 |
| Normalized Basic EPS | 1.48 | 0.61 | 0.35 | -0.58 | -1.80 |
| EPS Diluted | 2.39 | 1.24 | 0.44 | 0.11 | -6.12 |
| Normalized Diluted EPS | 1.34 | 0.58 | 0.33 | -0.60 | -1.81 |
| Average Basic Shares Outstanding | 380.28M | 377.62M | 371.12M | 365.24M | 359.44M |
| Average Diluted Shares Outstanding | 407.18M | 395.84M | 384.29M | 373.88M | 362.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
